MC001 Receives FDA Fast Track Designation in Pancreatic Cancer

MC001, an investigational chemoimmunotherapy antibody-drug conjugate (ADC) developed by Medicovestor, has received FDA fast track designation for pancreatic cancer.¹

MC001 is designed to target folate receptor alpha (FRα), a protein expressed in pancreatic ductal adenocarcinoma (PDAC). The agent uses a proprietary ADoBind platform, which combines a dimeric IgG1 antibody scaffold with a cytotoxic payload to deliver targeted tumor-cell killing alongside antibody-mediated immune activity.²

“Patients with pancreatic cancer urgently need more effective treatment options. Fast track designation is expected to support the acceleration of MC001’s development and regulatory review, potentially shortening the path to patients,” said Seah H Lim, MD, PhD, founder and CEO of Medicovestor, in a news release.¹

Preclinical findings presented at the 2026 American Association for Cancer Research Annual Meeting evaluated MC001 in FRα-expressing PDAC models. In a single-dose mouse xenograft study, MC001 demonstrated approximately 5-fold greater tumor inhibition than its monomeric ADC counterpart at equivalent molar dosing. Tumor suppression persisted beyond 30 days after a single injection and was associated with improved overall survival in the model.² These findings are preliminary and do not establish clinical benefit in humans.

MC001 Advances Toward Phase 1 Study

The FDA cleared MC001’s investigational new drug application in October 2026, following completion of the agency’s initial 30-day review period without a clinical hold.³

Medicovestor is preparing to initiate an international, multicenter phase 1 study to evaluate MC001’s safety, tolerability, pharmacokinetics, and preliminary antitumor activity in patients with advanced or metastatic pancreatic cancer and other eligible FRα-expressing solid tumors.¹

ADC Development in Pancreatic Cancer

PDAC remains challenging to treat, particularly in advanced disease. In the phase 3 NAPOLI 3 trial (NCT04083235), NALIRIFOX improved median overall survival compared with gemcitabine plus nab-paclitaxel in previously untreated patients with metastatic PDAC. Median overall survival was 11.1 months with NALIRIFOX vs 9.2 months with gemcitabine plus nab-paclitaxel (HR, 0.83; 95% CI, 0.70-0.99).⁴

Other investigational approaches in pancreatic cancer include ADCs and antibody-based therapies targeting tumor-associated proteins. In May 2025, the FDA fast tracked EBC-129, a novel ADC, and in March 2024, PT886, a bispecific antibody targeting claudin 18.2 and CD47.